Clozapine Therapy and CYP Genotype

Dean L, Kane M.

2016 Jun 8 [updated 2021 May 26]. In: Pratt VM, Scott SA, Pirmohamed M, Esquivel B, Kane MS, Kattman BL, Malheiro AJ, editors. Medical Genetics Summaries [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2012–.

Targeting phosphatases as the next generation of disease modifying therapeutics for Parkinson's disease.

Braithwaite SP, Voronkov M, Stock JB, Mouradian MM.

Neurochem Int. 2012 Nov;61(6):899-906. doi: 10.1016/j.neuint.2012.01.031. Review.

Combination of olfactory test and substantia nigra transcranial sonopraphy in the differential diagnosis of Parkinson's disease: a pilot study from China.

Chen W, Tan YY, Hu YY, Zhan WW, Wu L, Lou Y, Wang X, Zhou Y, Huang P, Gao Y, Xiao Q, Chen SD.

Transl Neurodegener. 2012 Dec 26;1(1):25. doi: 10.1186/2047-9158-1-25.

Anti-dyskinetic mechanisms of amantadine and dextromethorphan in the 6-OHDA rat model of Parkinson's disease: role of NMDA vs. 5-HT1A receptors.

Paquette MA, Martinez AA, Macheda T, Meshul CK, Johnson SW, Berger SP, Giuffrida A.

Eur J Neurosci. 2012 Nov;36(9):3224-34. doi: 10.1111/j.1460-9568.2012.08243.x.

The role of vision in Parkinson's disease locomotion control: free walking task.

Vitório R, Lirani-Silva E, Barbieri FA, Raile V, Batistela RA, Stella F, Gobbi LT.

Gait Posture. 2012 Feb;35(2):175-9. doi: 10.1016/j.gaitpost.2011.09.002.

Transgenic expression and activation of PGC-1α protect dopaminergic neurons in the MPTP mouse model of Parkinson's disease.

Mudò G, Mäkelä J, Di Liberto V, Tselykh TV, Olivieri M, Piepponen P, Eriksson O, Mälkiä A, Bonomo A, Kairisalo M, Aguirre JA, Korhonen L, Belluardo N, Lindholm D.

Cell Mol Life Sci. 2012 Apr;69(7):1153-65. doi: 10.1007/s00018-011-0850-z.

An exploratory study of activity in veterans with Parkinson's disease.

Trail M, Petersen NJ, Nelson N, Lai EC.

J Neurol. 2012 Aug;259(8):1686-93.

Resting state functional connectivity of the striatum in Parkinson's disease.

Hacker CD, Perlmutter JS, Criswell SR, Ances BM, Snyder AZ.

Brain. 2012 Dec;135(Pt 12):3699-711. doi: 10.1093/brain/aws281.

Clinical trials of dementia with Lewy bodies and Parkinson's disease dementia.

Aarsland D, Ballard C, Rongve A, Broadstock M, Svenningsson P.

Curr Neurol Neurosci Rep. 2012 Oct;12(5):492-501. doi: 10.1007/s11910-012-0290-7.

A Swedish version of the 16-item Parkinson fatigue scale (PFS-16).

Hagell P, Rosblom T, Pålhagen S.

Acta Neurol Scand. 2012 Apr;125(4):288-92. doi: 10.1111/j.1600-0404.2011.01560.x.

No correlation of substantia nigra echogenicity and nigrostriatal degradation in Parkinson's disease.

Lobsien E, Schreiner S, Plotkin M, Kupsch A, Schreiber SJ, Doepp F.

Mov Disord. 2012 Mar;27(3):450-3. doi: 10.1002/mds.24070.

Subjective sleep problems in patients with early Parkinson's disease.

Stefansdottir S, Gjerstad MD, Tysnes OB, Larsen JP.

Eur J Neurol. 2012 Dec;19(12):1575-81. doi: 10.1111/j.1468-1331.2012.03791.x.

The interhemispheric connections of the striatum: Implications for Parkinson's disease and drug-induced dyskinesias.

Lieu CA, Subramanian T.

Brain Res Bull. 2012 Jan 4;87(1):1-9. doi: 10.1016/j.brainresbull.2011.09.013. Review.

A rapid non invasive L-DOPA-¹³C breath test for optimally suppressing extracerebral AADC enzyme activity - toward individualizing carbidopa therapy in Parkinson’s disease.

Modak A, Durso R, Josephs E, Rosen D.

J Parkinsons Dis. 2012;2(4):349-56.

Role of glutathione S-transferase T1, M1 and P1 polymorphisms in Indian Parkinson's disease patients.

Biswas A, Sadhukhan T, Bose K, Ghosh P, Giri AK, Das SK, Ray K, Ray J.

Parkinsonism Relat Disord. 2012 Jun;18(5):664-5. doi: 10.1016/j.parkreldis.2011.09.019. No abstract available.